GlassScriptPhysician profile
Clara E Krajnik
NPI 1316398076
$5,823.28
in general payments reported to CMS, 2019-2025
35 companies · $761 in 2025
The $761 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,615 · 2022: $2,589 · 2023: $441 · 2024: $418 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,181.53 | 2021-2022 | |
| Novo Nordisk INC | $1,104.94 | 2021-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $601.39 | 2021-2025 | |
| Lilly USA, LLC | $452.12 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $244.44 | 2021-2022 | |
| Abbott Laboratories | $224.95 | 2021-2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $211.98 | 2023-2024 | Ingrezza |
| Indivior INC. | $205.84 | 2024-2025 | Sublocade |
| Lucid Diagnostics INC. | $178.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.33 | 2021-2022 | |
| Boston Scientific Corporation | $165.35 | 2022 | |
| Amgen INC. | $159.53 | 2021-2025 | Repatha |
| Daiichi Sankyo INC. | $142.17 | 2021 | |
| Axsome Therapeutics, INC. | $109.53 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.38 | 2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $58.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $50.52 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $45.95 | 2021-2022 | |
| Braeburn INC. | $43.53 | 2025 | Brixadi |
| Astellas Pharma US INC | $34.98 | 2025 | Veozah |
| Alkermes, INC. | $33.50 | 2025 | Vivitrol |
| Glaxosmithkline, LLC. | $32.29 | 2021 | |
| Organon LLC | $32.07 | 2023 | Nexplanon |
| Amarin Pharma, INC. | $28.55 | 2021-2022 | |
| Sanofi Pasteur INC. | $26.36 | 2024 | |
| Optos, INC. | $21.70 | 2021 | |
| Seqirus USA INC | $20.94 | 2024 | Fluad, Flucelvax |
| Biohaven Pharmaceuticals, INC. | $20.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.06 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $15.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.25 | 2021 | |
| Exact Sciences Corporation | $14.74 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.49 | 2021 | |
| Phadia US INC. | $14.24 | 2021 | |
| Pfizer INC. | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Krajnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.